4/A: Pasithea Therapeutics Director Corrects Stock Option Exercise Price in Amended SEC Filing

Lawrence Steinman, a director of Pasithea Therapeutics Corp., filed an amended Form 4 to correct the exercise price of a stock option granted on March 1, 2024.

Summary

• Lawrence Steinman, a director of Pasithea Therapeutics Corp., filed an amended Form 4 with the SEC.
• The purpose of the amendment is to correct the exercise price of a stock option previously reported as $8.34 per share.
• The correct exercise price is $8.13 per share, based on the closing price of Pasithea Therapeutics' common stock on March 1, 2024.
• The stock option was granted on March 1, 2024, for 7,500 shares and expires on February 28, 2034.
• The shares vest at a rate of 33% annually, starting one year from the grant date, contingent on the director's continued service.
• A reverse stock split of 1-for-20 was effected on January 2, 2024, which adjusted the share amounts and exercise prices of outstanding equity awards.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing correcting a minor error. It doesn't contain information that would significantly impact investor sentiment positively or negatively.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It reflects adjustments made due to corporate actions like reverse stock splits.

Comparison to Industry Standards

• Stock options are a common form of executive compensation in the biotechnology industry, used to align management's interests with those of shareholders.
• Vesting schedules of three years are typical for stock options, incentivizing long-term commitment.
• Reverse stock splits are often undertaken by companies to increase their stock price to meet listing requirements or attract institutional investors; however, they can also signal financial distress.

Stakeholder Impact

• The correction of the stock option exercise price has a negligible impact on shareholders.
• The vesting schedule of the stock option incentivizes the director to remain with the company.

Key Dates

Keywords

Form 4, Pasithea Therapeutics, Stock Option, Director, Lawrence Steinman, Exercise Price, Amendment, Reverse Stock Split, Vesting